Pharmacotherapy or surgery as primary treatment for acromegaly?

Diego Ferone, Annamaria Colao, Art Jan Van Der Lely, Steven W J Lamberts

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

In recent years important progress has been made in the management of acromegaly due to the availability of effective and well tolerated drugs and to improved surgical techniques, resulting in a broader choice of therapeutic interventions. Although surgery in the hands of an experienced surgeon still represents the primary option for the majority of patients, the new formulations of somatostatin analogues and dopamine agonists have partially modified the primary therapeutic approach to this severe and disabling chronic disease. Therapy with somatostatin analogues has been shown to reduce morbidity and the mortality rate in patients with acromegaly, and currently in some patients this medical approach may be preferable to surgery. Although in selected patients individualised pharmacotherapy might represent the primary therapy, transsphenoidal surgery of microadenomas and noninvasive macroadenomas remains the primary option, since the remission rate is very high and the costs are relatively low in comparison with lifelong therapy with somatostatin analogues. However, the treatment schedule in acromegaly should consider criteria additional to tumour size and invasiveness, such as the age and the general clinical condition of the patient. Presurgical treatment with somatostatin analogues has been reported to reduce surgical complications and time of hospitalisation after the operation. Moreover, a multidisciplinary team of well trained specialists is needed in order to guarantee the most optimal quality of life and life expectancy for patients with acromegaly.

Original languageEnglish
Pages (from-to)81-92
Number of pages12
JournalDrugs and Aging
Volume17
Issue number2
Publication statusPublished - 2000

Fingerprint

Acromegaly
Drug Therapy
Somatostatin
Therapeutics
Dopamine Agonists
Life Expectancy
Appointments and Schedules
Hospitalization
Chronic Disease
Quality of Life
Morbidity
Costs and Cost Analysis
Mortality
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology
  • Geriatrics and Gerontology

Cite this

Ferone, D., Colao, A., Van Der Lely, A. J., & Lamberts, S. W. J. (2000). Pharmacotherapy or surgery as primary treatment for acromegaly? Drugs and Aging, 17(2), 81-92.

Pharmacotherapy or surgery as primary treatment for acromegaly? / Ferone, Diego; Colao, Annamaria; Van Der Lely, Art Jan; Lamberts, Steven W J.

In: Drugs and Aging, Vol. 17, No. 2, 2000, p. 81-92.

Research output: Contribution to journalArticle

Ferone, D, Colao, A, Van Der Lely, AJ & Lamberts, SWJ 2000, 'Pharmacotherapy or surgery as primary treatment for acromegaly?', Drugs and Aging, vol. 17, no. 2, pp. 81-92.
Ferone D, Colao A, Van Der Lely AJ, Lamberts SWJ. Pharmacotherapy or surgery as primary treatment for acromegaly? Drugs and Aging. 2000;17(2):81-92.
Ferone, Diego ; Colao, Annamaria ; Van Der Lely, Art Jan ; Lamberts, Steven W J. / Pharmacotherapy or surgery as primary treatment for acromegaly?. In: Drugs and Aging. 2000 ; Vol. 17, No. 2. pp. 81-92.
@article{8b04c779f6ac4f458bca75f486b7ba01,
title = "Pharmacotherapy or surgery as primary treatment for acromegaly?",
abstract = "In recent years important progress has been made in the management of acromegaly due to the availability of effective and well tolerated drugs and to improved surgical techniques, resulting in a broader choice of therapeutic interventions. Although surgery in the hands of an experienced surgeon still represents the primary option for the majority of patients, the new formulations of somatostatin analogues and dopamine agonists have partially modified the primary therapeutic approach to this severe and disabling chronic disease. Therapy with somatostatin analogues has been shown to reduce morbidity and the mortality rate in patients with acromegaly, and currently in some patients this medical approach may be preferable to surgery. Although in selected patients individualised pharmacotherapy might represent the primary therapy, transsphenoidal surgery of microadenomas and noninvasive macroadenomas remains the primary option, since the remission rate is very high and the costs are relatively low in comparison with lifelong therapy with somatostatin analogues. However, the treatment schedule in acromegaly should consider criteria additional to tumour size and invasiveness, such as the age and the general clinical condition of the patient. Presurgical treatment with somatostatin analogues has been reported to reduce surgical complications and time of hospitalisation after the operation. Moreover, a multidisciplinary team of well trained specialists is needed in order to guarantee the most optimal quality of life and life expectancy for patients with acromegaly.",
author = "Diego Ferone and Annamaria Colao and {Van Der Lely}, {Art Jan} and Lamberts, {Steven W J}",
year = "2000",
language = "English",
volume = "17",
pages = "81--92",
journal = "Drugs and Aging",
issn = "1170-229X",
publisher = "Springer International Publishing",
number = "2",

}

TY - JOUR

T1 - Pharmacotherapy or surgery as primary treatment for acromegaly?

AU - Ferone, Diego

AU - Colao, Annamaria

AU - Van Der Lely, Art Jan

AU - Lamberts, Steven W J

PY - 2000

Y1 - 2000

N2 - In recent years important progress has been made in the management of acromegaly due to the availability of effective and well tolerated drugs and to improved surgical techniques, resulting in a broader choice of therapeutic interventions. Although surgery in the hands of an experienced surgeon still represents the primary option for the majority of patients, the new formulations of somatostatin analogues and dopamine agonists have partially modified the primary therapeutic approach to this severe and disabling chronic disease. Therapy with somatostatin analogues has been shown to reduce morbidity and the mortality rate in patients with acromegaly, and currently in some patients this medical approach may be preferable to surgery. Although in selected patients individualised pharmacotherapy might represent the primary therapy, transsphenoidal surgery of microadenomas and noninvasive macroadenomas remains the primary option, since the remission rate is very high and the costs are relatively low in comparison with lifelong therapy with somatostatin analogues. However, the treatment schedule in acromegaly should consider criteria additional to tumour size and invasiveness, such as the age and the general clinical condition of the patient. Presurgical treatment with somatostatin analogues has been reported to reduce surgical complications and time of hospitalisation after the operation. Moreover, a multidisciplinary team of well trained specialists is needed in order to guarantee the most optimal quality of life and life expectancy for patients with acromegaly.

AB - In recent years important progress has been made in the management of acromegaly due to the availability of effective and well tolerated drugs and to improved surgical techniques, resulting in a broader choice of therapeutic interventions. Although surgery in the hands of an experienced surgeon still represents the primary option for the majority of patients, the new formulations of somatostatin analogues and dopamine agonists have partially modified the primary therapeutic approach to this severe and disabling chronic disease. Therapy with somatostatin analogues has been shown to reduce morbidity and the mortality rate in patients with acromegaly, and currently in some patients this medical approach may be preferable to surgery. Although in selected patients individualised pharmacotherapy might represent the primary therapy, transsphenoidal surgery of microadenomas and noninvasive macroadenomas remains the primary option, since the remission rate is very high and the costs are relatively low in comparison with lifelong therapy with somatostatin analogues. However, the treatment schedule in acromegaly should consider criteria additional to tumour size and invasiveness, such as the age and the general clinical condition of the patient. Presurgical treatment with somatostatin analogues has been reported to reduce surgical complications and time of hospitalisation after the operation. Moreover, a multidisciplinary team of well trained specialists is needed in order to guarantee the most optimal quality of life and life expectancy for patients with acromegaly.

UR - http://www.scopus.com/inward/record.url?scp=0033859575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033859575&partnerID=8YFLogxK

M3 - Article

C2 - 10984197

AN - SCOPUS:0033859575

VL - 17

SP - 81

EP - 92

JO - Drugs and Aging

JF - Drugs and Aging

SN - 1170-229X

IS - 2

ER -